Pfizer announced detailed results from the first 2 pivotal Phase 3 trials of the OCTAVE program evaluating oral tofacitinib 10mg twice daily in inducing remission in adults with moderately to severely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback